GRI GRI
Company Profile ↓Company Overview
GRI (GRI) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.01.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | -95.73% |
| 6 Months: | -41.15% |
| 3 Months: | -34.62% |
| 1 Month: | -16.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.11 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 97.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 100.00K | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -1.16M | -1.14M | -1.03M | -2.60M | -2.31M | -1.25M | -2.63M | -189.00K | -186.00K | -988.00K | -5.93M | -2.44M | -1.90M | -2.26M | -2.13M | -3.05M | -2.90M | -3.37M | -2.00M |
| Net Income | -1.16M | -1.15M | -1.04M | -2.64M | -2.31M | -1.26M | -302.00K | -295.00K | -351.00K | -2.15M | -6.75M | -2.14M | -1.89M | -2.25M | -2.12M | -3.05M | -2.89M | -3.36M | -2.00M |
| Diluted EPS | - | -0.25 | -0.23 | -0.46 | -0.34 | -0.18 | -11.62 | -0.35 | -0.39 | -15.04 | -239.37 | -65.78 | -101.05 | -61.85 | -11.42 | -162.30 | -1.31 | -1.28 | -1.61 |
| R&D Expense | 883.00K | 808.00K | 733.00K | 1.77M | 1.20M | 215.00K | 1.27M | 59.00K | 63.00K | 116.00K | 880.00K | 1.19M | 933.00K | 877.00K | 1.12M | 1.64M | 1.88M | 1.77M | 361.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 100.00K | 0 | - | - | - | - |
| Operating Income | -4.79M | -9.26M | -2.24M | -11.39M | -8.23M | -11.98M |
| Net Income | -4.82M | -9.30M | -3.22M | -13.04M | -8.21M | -11.96M |
| Diluted EPS | -1.07 | -1.42 | -24.95 | -5,018.09 | -1,545.55 | -121.80 |
| R&D Expense | 3.71M | 5.19M | 242.00K | 3.23M | 3.77M | 6.82M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 955.00K | 8.34M | 383.00K | 2.96M | 5.74M | 8.67M |
| Total Equity | 3.21M | -1.45M | -4.85M | -1.62M | 259.00K | 4.03M | 6.01M |
| Cash & Equivalents | - | 109.00K | 3.70M | 9.00K | 1.81M | 5.03M | 8.23M |
| Total Liabilities | - | 2.41M | 2.52M | 2.01M | 2.70M | 1.71M | 2.66M |
| Current Liabilities | - | 2.23M | 2.44M | 1.99M | 2.70M | 1.64M | 2.64M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.71M | -8.31M | -1.08M | -8.99M | -8.61M | -10.19M |
| Investing Cash Flow | -2.00K | -3.84M | -3.00K | -8.00K | 0 | -3.00K |
| Financing Cash Flow | -4.00K | 15.75M | 1.01M | 10.80M | 11.83M | 13.39M |
| Capital Expenditure | -2.00K | -0 | -3.00K | -8.00K | -0 | -3.00K |
| Free Cash Flow | -3.71M | -8.31M | -1.09M | -9.00M | -8.61M | -10.19M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -4,788.0% | - | - | - | - | - |
| Net Margin % | -4,822.0% | - | - | - | - | - |
| ROE % | 331.6% | 191.9% | 198.0% | -5,033.6% | -203.5% | -199.0% |
| ROCE % | 377.0% | -157.2% | 139.0% | -4,396.5% | -200.7% | -198.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GRI
GRI Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTFAwMVRHZ1JZRlZwa0t1bmNpbExCM1dOcTBKWFVjM1FTWnpZR1ZvSUhQUEI5S2dvOFhXQ2JBb0FidjFEQ0hlWUVjSFBsN01laXY2Y1UxTnQ5bE1INEhIaGhDVXpDRGtxMUFUNmxFMTJxWGQ4OWJHMnZjUA?oc=5" target="_blank">GRI F…
GRI Bio Reports Positive Study Results For Chronic Lung Disease, But Stock Slumps 20% — What Happened? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOWWN0enBtUTZUVWFwMnJwUDQwaVBmNWl3SzZvU1ozdWx4T3Fxa201ZFVPUklyS2ozRHBiNTlqb2F1ZGswNldNTTgxM3BCXzM1Sm4wNWk3M3REREJXQV9kczdUcWJ0aHV6MWpjQm50OTRHYjBEb1NBcnNVbEF3TFQ1QXZKRk5WVGZKOVRpYj…
Grainger (LON:GRI) Stock Price Passes Above 200 Day Moving Average - Should You Sell? - MarketBeat
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPZFNmZ0laRkprRG05MmZwVWVCSzE1TGc5VzlLZFFvRG5MREEya0tIbEE2TDZHS2FiT1JjZmUwNTVENkdXV0lQUmdtZXB2dXhpSDRnd0xIMEQzelp1eHJnM3ktZEFaRjV5V0pjc2RHS0UtM25PV09BU2dKaDRJX2VoRjlxQlpZQVBkdzJRNm…
GRI|GRI Bio Inc|Price:1.457|Chg%:+0.077 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE1ERW51Yk5LbUFCOXdHUU1zT1puT3c3bmpmZkdGTWc2bTFET3JQWWdTazdULUNKaFFXcEpZX2ZvZmIwcHNUVnVfYW5xMjNVWXdCaWk3djBBcjd5WFREbFdvVTVwd2tmc2htUkVDbw?oc=5" target="_blank">GRI|GRI Bio Inc|Price…
GRI Bio CEO to detail immune cell modulator pipeline in Webull webinar Feb. 11 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxNS1JhWXFQV2lEVEd1Wldmd0VNeHp5MEJoVjVDWXNGTVM0UFJnNXc1VmtyUVFoYmNwVFFZSFRVanp5SjhrZFlxY3hZTFFPQnhWNjR0MVlMdV9yU2RVekJsaXVIblo4aHpXcHlNSlcwZ092UzNoaXpmckxJaGZuVHUweW1CV1l1RlVPQ0NmeU…
Grainger Stock And 2 Property Shares Tied To Rising Demand For Affordable Housing - simplywall.st
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNMTMzLUtGa1VIRG5HM19UcENodXNJUTZsaXFZR3pCWmxucVZ2MDMweHRxdl91VzYtR1E5M0szek9ndmVUMzFnaEdEbnhSbm95RUZlbFpaN3JRZ3Q1c0xLNlFtd01QWVJrMm9TMDJVM3ozNFhkM3BIYVNZY251UUg2MjJqRzZmZTF4eE4wVG…
GRI — Frequently Asked Questions
What is the current share price of GRI?
As of 2026-08-05 17:25 PDT, GRI trades at $1.53 on NASDAQ/NYSE. Its 52-week range is $1.38 to $63.28.
What is the P/E ratio of GRI?
GRI trades at a trailing price-to-earnings (P/E) ratio of -0.01.
Is GRI a good stock to buy?
This page provides a data-driven analysis of GRI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.